Base de dados : MEDLINE
Pesquisa : E02.120.527 [Categoria DeCS]
Referências encontradas : 594 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 60 ir para página                         

  1 / 594 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28669992
[Au] Autor:Ruggenenti P; Fervenza FC; Remuzzi G
[Ad] Endereço:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Via Stezzano 87, 24126 Bergamo, Italy.
[Ti] Título:Treatment of membranous nephropathy: time for a paradigm shift.
[So] Source:Nat Rev Nephrol;13(9):563-579, 2017 Sep.
[Is] ISSN:1759-507X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In patients with membranous nephropathy, alkylating agents (cyclophosphamide or chlorambucil) alone or in combination with steroids achieve remission of nephrotic syndrome more effectively than conservative treatment or steroids alone, but can cause myelotoxicity, infections, and cancer. Calcineurin inhibitors can improve proteinuria, but are nephrotoxic. Most patients relapse after treatment withdrawal and can become treatment dependent, which increases the risk of nephrotoxicity. The discovery of nephritogenic autoantibodies against podocyte M-type phospholipase A2 receptor (PLA R) and thrombospondin type-1 domain- containing protein 7A (THSD7A) antigens provides a clear pathophysiological rationale for interventions that specifically target B-cell lineages to prevent antibody production and subepithelial deposition. The anti-CD20 monoclonal antibody rituximab is safe and achieves remission of proteinuria in approximately two-thirds of patients with membranous nephropathy. In those with PLA R-related disease, remission can be predicted by anti-PLA R antibody depletion and relapse by antibody re-emergence into the circulation. Thus, integrated evaluation of serology and proteinuria could guide identification of affected patients and treatment with individually tailored protocols. Nonspecific and toxic immunosuppressive regimens will fall out of use. B-cell modulation by rituximab and second-generation anti-CD20 antibodies (or plasma cell-targeted therapy in anti-CD20 resistant forms of disease) will lead to a novel therapeutic paradigm for patients with membranous nephropathy.
[Mh] Termos MeSH primário: Glomerulonefrite Membranosa/terapia
[Mh] Termos MeSH secundário: Linfócitos B
Ensaios Clínicos como Assunto
Ciclofosfamida/uso terapêutico
Seres Humanos
Fatores Imunológicos/uso terapêutico
Imunossupressão
Imunossupressores/uso terapêutico
Procedimentos de Redução de Leucócitos
Rituximab/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunologic Factors); 0 (Immunosuppressive Agents); 4F4X42SYQ6 (Rituximab); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1038/nrneph.2017.92


  2 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28634323
[Au] Autor:Wu SC; Cao ZS; Chang KM; Juang JL
[Ad] Endereço:Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli, 35053, Taiwan.
[Ti] Título:Intestinal microbial dysbiosis aggravates the progression of Alzheimer's disease in Drosophila.
[So] Source:Nat Commun;8(1):24, 2017 06 20.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Neuroinflammation caused by local deposits of Aß in the brain is key for the pathogenesis and progression of Alzheimer's disease. However, inflammation in the brain is not always a response to local primary insults. Gut microbiota dysbiosis, which is recently emerging as a risk factor for psychiatric disorders, can also initiate a brain inflammatory response. It still remains unclear however, whether enteric dysbiosis also contributes to Alzheimer's disease. Here we show that in a Drosophila Alzheimer's disease model, enterobacteria infection exacerbated progression of Alzheimer's disease by promoting immune hemocyte recruitment to the brain, thereby provoking TNF-JNK mediated neurodegeneration. Genetic depletion of hemocytes attenuates neuroinflammation and alleviated neurodegeneration. We further found that enteric infection increases the motility of the hemocytes, making them more readily attracted to the brain with an elevated oxidative stress status. This work highlights the importance of gut-brain crosstalk as a fundamental regulatory system in modulating Alzheimer's disease neurodegeneration.Emerging evidence suggests that gut microbiota influences immune function in the brain and may play a role in neurological diseases. Here, the authors offer in vivo evidence from a Drosophila model that supports a role for gut microbiota in modulating the progression of Alzheimer's disease.
[Mh] Termos MeSH primário: Doença de Alzheimer/microbiologia
Encéfalo/microbiologia
Drosophila melanogaster/microbiologia
Disbiose/microbiologia
Infecções por Enterobacteriaceae/microbiologia
Trato Gastrointestinal/microbiologia
[Mh] Termos MeSH secundário: Doença de Alzheimer/complicações
Doença de Alzheimer/imunologia
Doença de Alzheimer/patologia
Peptídeos beta-Amiloides/genética
Peptídeos beta-Amiloides/imunologia
Animais
Peptídeos Catiônicos Antimicrobianos/genética
Peptídeos Catiônicos Antimicrobianos/imunologia
Encéfalo/imunologia
Encéfalo/patologia
Movimento Celular/imunologia
Modelos Animais de Doenças
Progressão da Doença
Proteínas de Drosophila/genética
Proteínas de Drosophila/imunologia
Drosophila melanogaster/imunologia
Disbiose/complicações
Disbiose/imunologia
Disbiose/patologia
Enterobacteriaceae/crescimento & desenvolvimento
Enterobacteriaceae/imunologia
Infecções por Enterobacteriaceae/complicações
Infecções por Enterobacteriaceae/imunologia
Infecções por Enterobacteriaceae/patologia
Trato Gastrointestinal/imunologia
Regulação da Expressão Gênica
Hemócitos/imunologia
Hemócitos/microbiologia
Hemócitos/patologia
Seres Humanos
Procedimentos de Redução de Leucócitos
MAP Quinase Quinase 4/genética
MAP Quinase Quinase 4/imunologia
Microbiota/imunologia
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/imunologia
Transdução de Sinais
Fator de Necrose Tumoral alfa/genética
Fator de Necrose Tumoral alfa/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Antimicrobial Cationic Peptides); 0 (Drosophila Proteins); 0 (Peptide Fragments); 0 (Tumor Necrosis Factor-alpha); 0 (amyloid beta-protein (1-42)); EC 2.7.12.2 (MAP Kinase Kinase 4)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170622
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-00040-6


  3 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28419477
[Au] Autor:Jimenez-Marco T; Cancino-Faure B; Girona-Llobera E; Alcover MM; Riera C; Fisa R
[Ad] Endereço:Fundació Banc de Sang i Teixits de las Illes Balears, Majorca.
[Ti] Título:The effectiveness of riboflavin and ultraviolet light pathogen reduction technology in eliminating Trypanosoma cruzi from leukoreduced whole blood.
[So] Source:Transfusion;57(6):1440-1447, 2017 Jun.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The parasitic Chagas disease is caused by the protozoan Trypanosoma cruzi, which is mainly transmitted by insect vectors. Other infection routes, both in endemic and in nonendemic areas, include organ and marrow transplantation, congenital transmission, and blood transfusion. Asymptomatic chronic chagasic individuals may have a low and transient parasitemia in peripheral blood and, consequently, they can unknowingly transmit the disease via blood transfusion. Riboflavin and ultraviolet (UV) light pathogen reduction is a method to reduce pathogen transfusion transmission risk based on damage to the pathogen nucleic acids. STUDY DESIGN AND METHODS: In this study, we tested the effectiveness of this technology for the elimination of T. cruzi parasites in artificially contaminated whole blood units (WBUs) and thus for decreasing the risk of T. cruzi transfusion transmission. The contaminated WBUs were leukoreduced by filtration and treated with riboflavin and UV light. The level of pathogen reduction was quantified by a real-time polymerase chain reaction (qPCR) and a real-time reverse transcription-polymerase chain reaction (RT-qPCR) as a viability assay. RESULTS: The RNA (cDNA) quantification of the parasites showed a more than 99% reduction of viable T. cruzi parasites after leukoreduction and a complete reduction (100%) after the riboflavin and UV light treatment. CONCLUSION: Riboflavin and UV light treatment and leukoreduction used in conjunction appears to eliminate significant amounts of viable T. cruzi in whole blood. Both strategies could complement other blood bank measures already implemented to prevent the transmission of T. cruzi via blood transfusion.
[Mh] Termos MeSH primário: Procedimentos de Redução de Leucócitos/métodos
Riboflavina/farmacologia
Trypanosoma cruzi/efeitos dos fármacos
Trypanosoma cruzi/efeitos da radiação
Raios Ultravioleta
[Mh] Termos MeSH secundário: Preservação de Sangue/métodos
Doença de Chagas/prevenção & controle
Trypanosoma cruzi/patogenicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
TLM2976OFR (Riboflavin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14071


  4 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28320832
[Au] Autor:Lee MC; McCubbin JA; Christensen AD; Poole DP; Rajasekhar P; Lieu T; Bunnett NW; Garcia-Caraballo S; Erickson A; Brierley SM; Saleh R; Achuthan A; Fleetwood AJ; Anderson RL; Hamilton JA; Cook AD
[Ad] Endereço:Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria 3050, Australia.
[Ti] Título:G-CSF Receptor Blockade Ameliorates Arthritic Pain and Disease.
[So] Source:J Immunol;198(9):3565-3575, 2017 May 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:G-CSF or CSF-3, originally defined as a regulator of granulocyte lineage development via its cell surface receptor (G-CSFR), can play a role in inflammation, and hence in many pathologies, due to its effects on mature lineage populations. Given this, and because pain is an extremely important arthritis symptom, the efficacy of an anti-G-CSFR mAb for arthritic pain and disease was compared with that of a neutrophil-depleting mAb, anti-Ly6G, in both adaptive and innate immune-mediated murine models. Pain and disease were ameliorated in Ag-induced arthritis, zymosan-induced arthritis, and methylated BSA/IL-1 arthritis by both prophylactic and therapeutic anti-G-CSFR mAb treatment, whereas only prophylactic anti-Ly6G mAb treatment was effective. Efficacy for pain and disease correlated with reduced joint neutrophil numbers and, importantly, benefits were noted without necessarily the concomitant reduction in circulating neutrophils. Anti-G-CSFR mAb also suppressed zymosan-induced inflammatory pain. A new G-CSF-driven (methylated BSA/G-CSF) arthritis model was established enabling us to demonstrate that pain was blocked by a cyclooxygenase-2 inhibitor, suggesting an indirect effect on neurons. Correspondingly, dorsal root ganglion neurons cultured in G-CSF failed to respond to G-CSF in vitro, and gene expression could not be detected in dorsal root ganglion neurons by single-cell RT-PCR. These data suggest that G-CSFR/G-CSF targeting may be a safe therapeutic strategy for arthritis and other inflammatory conditions, particularly those in which pain is important, as well as for inflammatory pain per se.
[Mh] Termos MeSH primário: Anticorpos Bloqueadores/uso terapêutico
Artrite Experimental/terapia
Artrite Reumatoide/terapia
Imunoterapia/métodos
Neurônios/efeitos dos fármacos
Neutrófilos/imunologia
Receptores de Fator Estimulador de Colônias de Granulócitos/metabolismo
[Mh] Termos MeSH secundário: Animais
Antígenos Ly/imunologia
Artrite Experimental/induzido quimicamente
Artrite Experimental/imunologia
Artrite Reumatoide/imunologia
Células Cultivadas
Modelos Animais de Doenças
Fator Estimulador de Colônias de Granulócitos/metabolismo
Seres Humanos
Procedimentos de Redução de Leucócitos
Camundongos
Camundongos Endogâmicos C57BL
Neurônios/fisiologia
Neutrófilos/efeitos dos fármacos
Neutrófilos/patologia
Manejo da Dor
Receptores de Fator Estimulador de Colônias de Granulócitos/genética
Receptores de Fator Estimulador de Colônias de Granulócitos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Blocking); 0 (Antigens, Ly); 0 (Ly6G antigen, mouse); 0 (Receptors, Granulocyte Colony-Stimulating Factor); 143011-72-7 (Granulocyte Colony-Stimulating Factor)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170501
[Lr] Data última revisão:
170501
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170322
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1602127


  5 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28263170
[Au] Autor:Silliman CC; Burke T; Kelher MR
[Ad] Endereço:Bonfils Blood Center, Denver, CO, United States of America.
[Ti] Título:The accumulation of lipids and proteins during red blood cell storage: the roles of leucoreduction and experimental filtration.
[So] Source:Blood Transfus;15(2):131-136, 2017 Mar.
[Is] ISSN:1723-2007
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Pre-storage leucoreduction has been universally adopted in most developed countries in Asia, Europe and the Americas. It decreases febrile transfusion reactions, alloimmunisation to HLA antigens, cytomegalovirus exposure, the accumulation of a number of pro-inflammatory mediators in the supernatant, including the accumulation of platelet-and leucocyte-derived proteins and metabolites during routine storage. This review will highlight the lipids and proteins, biological response modifiers (BRMs) that accumulate, their clinical effects in transfused hosts, and methods of mitigation.
[Mh] Termos MeSH primário: Lesão Pulmonar Aguda
Preservação de Sangue/efeitos adversos
Proteínas Sanguíneas/metabolismo
Transfusão de Eritrócitos/efeitos adversos
Eritrócitos/metabolismo
Procedimentos de Redução de Leucócitos
Metabolismo dos Lipídeos
[Mh] Termos MeSH secundário: Lesão Pulmonar Aguda/sangue
Lesão Pulmonar Aguda/etiologia
Lesão Pulmonar Aguda/terapia
Preservação de Sangue/métodos
Transfusão de Eritrócitos/métodos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Blood Proteins)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170316
[Lr] Data última revisão:
170316
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE
[do] DOI:10.2450/2017.0314-16


  6 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28130849
[Au] Autor:Petersson A; Ekblom K
[Ad] Endereço:Department of Clinical Chemistry and Transfusion Medicine, Växjö Central Hospital, Växjö, Sweden.
[Ti] Título:Methods for counting residual leukocytes in leukocyte-depleted plasma-a comparison between a routine hematology instrument, the Nageotte chamber, flow cytometry, and a fluorescent microscopy analyzer.
[So] Source:Transfusion;57(5):1192-1198, 2017 May.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Counting very low levels of leukocytes is technically challenging but mandatory for quality control of leukocyte-depleted plasma. Established assays, such as flow cytometry and counting in the Nageotte chamber, are laborious and expensive. The aim of this study was to test two alternative assays, the cerebrospinal fluid program in the routine hematology analyzer ADVIA 2120 and a fluorescence microscopy analyzer, the ADAM-rWBC. STUDY DESIGN AND METHODS: Linearity, accuracy, and precision were established for the ADVIA 2120, the ADAM-rWBC analyzer and the Nageotte chamber with flow cytometry as the reference method. Two hundred consecutive leukocyte-depleted donor plasma samples were also tested. RESULTS: The ADAM-rWBC analyzer and the Nageotte chamber fulfilled all quality requirements. Flow cytometry fulfilled the requirements for linearity and precision. The ADVIA 2120 analyzer did not fully reach the quality criteria, and flow cytometry did not reach quality criteria on accuracy. No false-positive results on donor plasma samples were recorded. CONCLUSION: The ADAM-rWBC is suitable for the purpose of quality control of residual leukocytes in leukocyte-depleted plasma. For the ADVIA 2120, further improvements and studies are needed to reach the quality requirements stated in this study.
[Mh] Termos MeSH primário: Contagem de Leucócitos/métodos
Procedimentos de Redução de Leucócitos/normas
Plasma/citologia
[Mh] Termos MeSH secundário: Doadores de Sangue
Citometria de Fluxo/métodos
Citometria de Fluxo/normas
Hematologia/instrumentação
Hematologia/métodos
Hematologia/normas
Seres Humanos
Microscopia de Fluorescência/métodos
Microscopia de Fluorescência/normas
Controle de Qualidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170129
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14007


  7 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28007877
[Au] Autor:Lindblom RPF; Tovedal T; Norlin B; Hillered L; Popova SN; Alafuzoff I; Thelin S
[Ad] Endereço:Department of Cardiothoracic Surgery and Anesthesia, Uppsala University Hospital, Uppsala, Sweden.
[Ti] Título:Mechanical reperfusion with leucocyte-filtered blood does not prevent injury following global cerebral ischaemia.
[So] Source:Eur J Cardiothorac Surg;51(4):773-782, 2017 04 01.
[Is] ISSN:1873-734X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Objectives: Prolonged global cerebral ischaemia leads to irreversible injury, often with lethal outcome. Brain injuries are partly caused by the uncontrolled reperfusion that occurs once the circulation is re-established. Recent animal experiments suggest that controlled reperfusion following lengthy ischaemia might prevent severe brain injury. This study aimed at further exploring cerebral alterations and outcome following prolonged global cerebral ischaemia and mechanically manipulated reperfusion. Methods: Three groups of pigs were included; one sham operated ( n = 3) and two that underwent 30-min global cerebral ischaemia. All vessels that supply the brain were isolated intrathoracically, after which they were occluded for 30 min in the ischaemic groups. In one of the ischaemic groups uncontrolled reperfusion was applied (URep, n = 6), i.e. normal circulation was restored 30 min after arrested cerebral circulation. The second ischaemic group received mechanical reperfusion (MRep, n = 6) with leucocyte-filtered blood at constant flow and pressure for 20 min using extracorporeal circulation following the 30-min ischaemia, after which normal blood flow resumed. All animals were monitored for 3 h after start of uncontrolled reperfusion. Haemodynamic parameters, arterial and sagittal sinus blood gases, cerebral oxygen extraction rates and intraparenchymal biomarkers using microdialysis were measured. Brain histology was performed post-mortem. Results: Global brain ischaemia led to the same extent of severe morphological changes at the level of light microscopy in the two ischaemic experimental groups, regardless of reperfusion protocol. Furthermore, no significant differences were found between the URep and MRep groups regarding cerebral blood gases or microdialysis biomarkers. Conclusions: Mechanical reperfusion following the current protocol does not modify brain alterations caused by 30 min of arrested cerebral circulation.
[Mh] Termos MeSH primário: Isquemia Encefálica/complicações
Procedimentos de Redução de Leucócitos/métodos
Traumatismo por Reperfusão/prevenção & controle
Reperfusão/métodos
[Mh] Termos MeSH secundário: Animais
Encéfalo/patologia
Isquemia Encefálica/patologia
Isquemia Encefálica/fisiopatologia
Dióxido de Carbono/sangue
Circulação Cerebrovascular/fisiologia
Modelos Animais de Doenças
Filtração/métodos
Hemodinâmica/fisiologia
Masculino
Oxigênio/sangue
Pressão Parcial
Traumatismo por Reperfusão/etiologia
Traumatismo por Reperfusão/patologia
Traumatismo por Reperfusão/fisiopatologia
Sus scrofa
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
142M471B3J (Carbon Dioxide); S88TT14065 (Oxygen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161224
[St] Status:MEDLINE
[do] DOI:10.1093/ejcts/ezw367


  8 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28430958
[Au] Autor:Finlay L; Nippak P; Tiessen J; Isaac W; Callum J; Cserti-Gazdewich C
[Ad] Endereço:From the Department of Clinical Pathology, Sunnybrook Health Science Centre, Toronto, Canada.
[Ti] Título:Survey of Institutional Policies for Provision of "CMV-Safe" Blood in Ontario.
[So] Source:Am J Clin Pathol;146(5):578-584, 2016 Nov 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: Debate continues on whether leukoreduction alone (LR) is sufficiently similar to leukoreduced cellular products drawn from cytomegalovirus (CMV)-seronegative (SN) donors to minimize the risk of transfusion-transmitted CMV (TT-CMV). We sought to determine the policy, inventory, and practice landscape of the province for TT-CMV mitigation. Methods: A web-based survey was distributed to hospitals in Ontario by Canadian Blood Services to collect data on their policies with respect to TT-CMV prevention. Results: TT-CMV mitigation practices varied by patient population, hospital size, and region. Smaller institutions remain committed to dual prevention, whereas academic hospitals favor a single-measure approach. Although smaller institutions attempt to align their policies with leadership sites, emulation is often inaccurate. The demands for SN products also appear to be significantly lower than the current screening practices of Canadian Blood Services. Conclusions: Standardization is lacking on practices to prevent TT-CMV. Although there are barriers to harmonizing practices, the apparent shift to policies acknowledging LR as a sufficient protection is likely to continue.
[Mh] Termos MeSH primário: Transfusão de Sangue
Infecções por Citomegalovirus/prevenção & controle
Citomegalovirus/imunologia
Política Organizacional
[Mh] Termos MeSH secundário: Bancos de Sangue
Doadores de Sangue
Segurança do Sangue
Transfusão de Sangue/economia
Criança
Estudos Transversais
Citomegalovirus/isolamento & purificação
Infecções por Citomegalovirus/transmissão
Infecções por Citomegalovirus/virologia
Feminino
Infecções por HIV/complicações
Infecções por HIV/imunologia
Instalações de Saúde
Seres Humanos
Hospedeiro Imunocomprometido
Recém-Nascido
Procedimentos de Redução de Leucócitos
Ontário
Gravidez
Inquéritos e Questionários
Reação Transfusional
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqw181


  9 / 594 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27994256
[Au] Autor:Barchilon M; Gaspar C; Mexas A; Nieter D
[Ad] Endereço:College of Veterinary Medicine, Midwestern University, Glendale, Arizona, Midwestern University College of Health Sciences, Glendale, Arizona.
[Ti] Título:A Novel Centrifugation Method Using a Cell Salvage Device Offers an Alternative to the Use of Leukocyte-Depleting Filters for Autologous Blood Transfusions.
[So] Source:J Extra Corpor Technol;48(4):168-172, 2016 12.
[Is] ISSN:0022-1058
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Autotransfusion protocols often use the use of costly filters, such as leukocyte-depleting filters (LDFs), to minimize reinfusion of activated leukocytes and inflammatory mediators associated with reperfusion injury (RI). LDFs are used extensively in hospital settings; however, they represent an additional capital expenditure for hospitals, as well as a constraint on the reinfusion rate of blood products for health-care providers. We compared a commonly used LDF to a novel centrifugation method employing a widely used cell salvage device. Complete blood counts and enzyme-linked immunosorbent assays (ELISAs) measuring tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2) were performed to compare the efficacy of these methodologies. The LDF removed, on average, 94% of all leukocytes, including 96% of neutrophils. The centrifugation method removed, on average, 89% of all leukocytes, including 91% of neutrophils and resulted in a highly concentrated red blood cell product. Our results suggest both methods offer equivalent leukocyte reduction. TNF-α was also comparably reduced following our novel centrifugation method and the LDF method and IL-2 levels were undetectable in all samples. These results indicate our novel centrifugation method may preclude the need for a LDF during select autotransfusion applications.
[Mh] Termos MeSH primário: Transfusão de Sangue Autóloga/instrumentação
Centrifugação/instrumentação
Procedimentos de Redução de Leucócitos/instrumentação
Leucócitos/citologia
Recuperação de Sangue Operatório/instrumentação
Ultrafiltração/instrumentação
[Mh] Termos MeSH secundário: Animais
Transfusão de Sangue Autóloga/métodos
Bovinos
Células Cultivadas
Desenho de Equipamento
Análise de Falha de Equipamento
Contagem de Leucócitos
[Pt] Tipo de publicação:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:161221
[St] Status:MEDLINE


  10 / 594 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27733759
[Au] Autor:Dörner T; Lipsky PE
[Ad] Endereço:Departments of Medicine, Rheumatology and Clinical Immunology, Charité-University Medicine Berlin and the German Rheumatism Research Centre (DRFZ), Chariteplatz 01, Berlin 10117, Germany.
[Ti] Título:Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.
[So] Source:Nat Rev Rheumatol;12(11):645-657, 2016 Nov.
[Is] ISSN:1759-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:New insights into the mechanisms of autoimmune diseases have been obtained not only from preclinical studies, but also from clinical trials of pan-B-cell-directed therapy. Overall, the results of these clinical trials suggest that more-specific approaches focusing on pathogenic B-cell functions, and perhaps sparing or even enhancing regulatory B-cell activity, might be attractive alternatives. Importantly, pathogenic B-cell subpopulations function within a network of cellular interactions, many of which might require additional interventions to restore immunologic balance and suppress autoimmune disease. Thus, approaches that simultaneously target innate immune cells as well as multiple nodes of T-cell and B-cell interactions might hold the promise of improved therapeutic efficacy. Interfering with B-cell intracellular signalling pathways, altering their intracellular metabolic pathways and perturbing transcription factors are additional options. This Review critically analyses these approaches, examines the role of cytokines and other functions of B-lineage cells separate from antibody secretion, and provides insights into the potential next generation of therapies targeting B-lineage cells.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Linfócitos B/imunologia
Lúpus Eritematoso Sistêmico/tratamento farmacológico
Lúpus Eritematoso Sistêmico/imunologia
[Mh] Termos MeSH secundário: Antígenos CD20/imunologia
Fator Ativador de Células B/imunologia
Ensaios Clínicos como Assunto
Citocinas/imunologia
Medicina Baseada em Evidências
Seres Humanos
Procedimentos de Redução de Leucócitos/métodos
Linfócitos T/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antigens, CD20); 0 (B-Cell Activating Factor); 0 (Cytokines)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170622
[Lr] Data última revisão:
170622
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161014
[St] Status:MEDLINE
[do] DOI:10.1038/nrrheum.2016.158



página 1 de 60 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde